RSV Vaccines, Nirsevimab Tied to Reduced RSV-Linked Hospitalization

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on May 14, 2025.

By Elana Gotkine HealthDay Reporter

TUESDAY, May 13, 2025 -- Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated hospitalization rates among infants aged 0 to 7 months during the 2024-2025 RSV season, the first season that the maternal vaccine and nirsevimab were widely available, according to research published in the May 8 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

Monica E. Patton, M.D., from the CDC in Atlanta, and colleagues used data from the RSV-Associated Hospitalization Surveillance Network (RSV-NET) and New Vaccine Surveillance Network (NVSN) to examine the association between availability of maternal RSV vaccine and nirsevimab and infant and child RSV-associated hospitalization rates by comparing the rates among children aged younger than 5 years for the 2024-2025 and 2018-2020 RSV seasons.

The researchers found that compared with 2018-2020 pooled rates, 2024-2025 RSV-associated hospitalization rates were lower among infants aged 0 to 7 months (eligible for protection with maternal vaccination or nirsevimab; estimated rate reductions of 43 and 28 percent for RSV-NET and NVSN, respectively). Infants aged 0 to 2 months had the largest estimated rate reduction (52 and 45 percent for RSV-NET and NVSN, respectively); large reductions were also seen during peak hospitalization periods (December to February).

"These findings highlight the importance of effective annual health care planning to implement Advisory Committee on Immunization Practices' recommendations for RSV prevention products and ensure parents can protect infants as early as possible in the RSV season, either through maternal vaccination during pregnancy or infant receipt of nirsevimab," the authors write. "For infants born during the RSV season who are not protected through maternal vaccination, nirsevimab should be administered within the first week of life, ideally during the birth hospitalization."

Several authors disclosed ties to the biopharmaceutical and medical technology industries.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-05-14 12:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords